Module

Summary of Mutations Associated With Resistance to HBV Drugs

Source: Clinical Strategies for Preventing and Managing Resistance to Anti-HBV Agents

Summary of Mutations Associated With Resistance to HBV Drugs

Faculty:
T. Jake Liang, MD

CME CREDIT INFORMATION

Release Date: 04/14/06

Expiration Date: 04/13/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review nucleos(t)ide analogue drug resistance mutations in HBV polymerase
Define the 3 groups of nucleos(t)ide analogues used in the treatment of HBV infection
Discuss cross-resistance to anti-HBV drugs

Topics covered include:

Introduction
Nucleos(t)ide Analogues
HBV Polymerase Protein and Resistance Mutations
HBV Polymerase Protein and Resistance Mutations: Lamivudine resistance
HBV Polymerase Protein and Resistance Mutations: Adefovir resistance
HBV Polymerase Protein and Resistance Mutations: Entecavir resistance
HBV Polymerase Protein and Resistance Mutations: Other resistance mutations
HBV Polymerase Protein and Resistance Mutations: Combination therapy
HBV Polymerase Protein and Resistance Mutations: Cross-resistance

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.